OmniAb, Inc. (OABI) Earnings Call Transcript & Summary
May 8, 2025
Earnings Call Speaker Segments
Kurt Gustafson
executiveThanks, Operator, and good afternoon to all of you. I'm Kurt Gustafson, serving as Chief Financial Officer at OmniAb, and I appreciate each of you for dialing into our conference call covering First Quarter 2025 Financial Results. Slides have been prepared to go along with the remarks we've prepared for today, and you can find them on our site, www.omniab.com. Prior to getting started, I want to remind those listening that remarks given by management on this call will contain forward-looking statements as defined under the federal securities laws. Risks and uncertainties are involved in these forward-looking statements, and those could make actual results differ materially from any results that are anticipated. The cautionary statements included in today's press release, along with our SEC files, qualify these forward-looking statements. It's important to note that time-sensitive information is contained in this conference call, and it is accurate only as of today's live broadcast date, May 8th, 2025. Unless the law requires it, OmniAb assumes no obligation to revise or update any forward-looking statements so they reflect events or circumstances occurring after this call's date. With me on today's call are Matt Foehr, who serves as OmniAb's President and CEO, and Bob Chen, our Vice President of Discovery Systems. On today's call, we will share highlights regarding the company's business and operations, updates on partners and technology, and our recent financial results. Once the prepared remarks are finished, we'll open up the call for questions. I'll now hand things over to Matt.
Matt Foehr
executiveThank you, Kurt. Hello, everyone, and I appreciate you being with us on today's call. The year 2025 has begun quite well and is proceeding in line with what we anticipated. Even with certain disruptions occurring across the wider environment and within our sector, we keep bringing on additional partners, and the set of partnered programs we have continues both to expand and to move forward. The volume of deals since the year began has been robust, encompassing platform agreements as well as more recent asset-based arrangements, and I have found both the speed and the caliber of these deals impressive. On the whole, we feel that our business's underpinnings are becoming more solid. What we offer technologically can be leveraged to a great degree, sets us apart, and keeps growing. As we said before, we tightened up our operations during the early portion of Q1, and our attention stays fixed on generating value for our partners and for every one of our stakeholders. We have observed encouraging advancement and positive results from numerous partners, and today we are likewise pleased to discuss a further technology achievement for the firm, namely the introduction of the Exploration Partner Access Program, which permits OmniAb partners to buy Exploration instruments so they can be used in their own laboratories. Here at OmniAb, our dedication to fueling innovation that supports drug discovery has never wavered. A portion of that innovation involves creating and honing the tools employed in our own processes, which boost speed, precision, and effectiveness. Exploration has formed a key element of our efforts at this company for a long stretch of time; we showcased Exploration a few years ago during an analyst event held in San Francisco, and we have kept improving both the hardware and the software even as it functioned as the core of our in-house screening operations. I will now briefly mention only a handful of our metrics before handing the call to Bob, who will discuss certain technical details regarding Exploration. Let's proceed to slide number five, covering active partners. We wrapped up Q1 with 95 partners actively working with us, and that figure takes into account new deals signed with Harvard Wyss Institute, Tacus Biotech, and Orion Corporation. What makes the Orion deal notable is that it centers on a single ion channel antibody program. Once the quarter was over, we also completed — as a matter of fact, just today — an asset transaction with Angelini Pharma covering a small molecule ion channel modulator that targets KV7.2. As you might recall, Roche had handed this program back to us near the end of last year. Through the terms we agreed on with Angelini, we expect to receive $3 million as an upfront payment, plus the chance to earn over $170 million in contractual milestones and a royalty on top of that. Turning to slide six, our count of active programs likewise increased during the first quarter. It was gratifying to note that the surge in program additions we saw in Q4 of last year carried over into Q1 of this year, and the overall tally of active programs climbed to 378 by the close of the quarter. I want to point out, as we typically do, that losing programs or having them terminated is clearly a normal aspect of drug development, and during Q1 we experienced that as well, with the majority happening at the discovery stage, which is what you'd generally anticipate. Now on slide seven: when Q1 wrapped up, our partners had 33 active clinical programs along with approved products. During the first quarter, GenMab added a single new clinical program, and you'll find it shown on the pipeline chart in the appendix of today's presentation materials. As for the rest of the year, we still expect five to seven new entries into clinical development in total. Looking at slide eight, you can see the expansion of our post-discovery stage asset portfolio; Q1 brought several advancements, including fresh assets advancing to preclinical development, one new program entering phase one as I mentioned earlier, and another now sitting in phase three — SAL003, an anti-PCSK9 antibody partnered with Salubris Pharmaceuticals; Wuji discovered that antibody leveraging our OmniRAT platform, and for this phase three stage program we retain a 3% royalty. Also worth noting, Teva has disclosed that PEV408 moved from phase one into phase two, launching a new study focused on safety and efficacy in adults with celiac disease. Overall, it's good to see these post-discovery stage assets keep expanding — they're up over 39% across the past two years. We're still enthusiastic about the variety, the meaningful milestone opportunities ahead, and the possible therapeutic benefits of what sits in our preclinical stage bucket, shown in orange on the pie chart. Our expectation is that those will advance and fuel new clinical starts down the road. On slide nine here, we've called out a few recent and selected partner updates. Several of those announcements, along with encouraging data releases, took place during AACR last week. It's encouraging to keep watching the momentum, plus the significant sums our partners are putting into programs built on technology we've provided. In addition, we anticipate multiple presentations from partners at the ASCO annual meeting in Chicago, starting May 30th, and you can find a partial list of those in the appendix of today's slide deck too. Moving to slide 10, Bob and I will walk through additional specifics regarding the Exploration Partner Access Program, which we introduced today and which our press release, issued just after the market closed, outlined. Across our expanding partner ecosystem, awareness has grown that Exploration delivers considerable value, and partners have voiced a desire to fold it into the processes used in their own laboratories. Following extensive work on development and testing, including deployments that took place beyond our own laboratories, our assessment is that Exploration has now achieved a degree of technical maturity at which its reliability and capabilities will make a significant contribution to the screening instrument space, an area we regard as attracting growing interest within the industry. Preliminary discussions are already underway with a number of our partners, and the responses we have gotten back have been positive to an overwhelming degree. Our belief is that Exploration will let our partners improve and speed up the downstream work they do. Just as importantly, this new program holds the potential to generate additional revenue streams for us too. I'll now turn things over to Bob, and he'll walk us through more detail on a few of the important pieces of the Exploration technology. Bob.
Bob Chen
executiveThanks, Matt. I'll take it from slide 12. Exploration has played a key role in our discovery engine over the last several years, powering antibody discovery services for our partners. Once our partners witnessed this technology at work and saw the data it generates, they began asking, "How can we get one of those?" Those years spent supporting partner discovery have also allowed us to refine and mature the technology. That progress, together with field testing, has brought Exploration to a validated state in which the instrument can now be made available to partners for use in their own labs. During the analyst research and technology event Matt referenced earlier, we described Exploration as an instrument for antibody discovery that uses AI to conduct deep functional screening. For a long time, extracting primary B cells from immunized animals has posed a major challenge in discovering therapeutic antibodies. Older approaches tend to limit antibody diversity and can take several weeks to complete. With Exploration, however, we've cut that down to three steps. Slide 13 illustrates how it works: first, B cells get loaded onto a proprietary microcapillary array chip featuring a through-hole design containing 1.5 million microcapillaries, each just 40 microns across. These microcapillaries separate B cells so they can undergo different assays. Next, the chip goes into an instrument that automatically images each individual cell. The instrument relies on sophisticated AI-driven computer vision to spot promising hits whose attributes align with the antibody profile being sought, which brings accuracy and speed to the task of identifying the strongest candidates. After that, a touchless laser technique — precise and quick — is used to retrieve the hits, sorting cells out of the microcapillaries and depositing them onto a recovery plate. Sequencing of the antibodies from the sorted cells follows once recovery has finished. Technically speaking, and as outlined here on slide 14, our view is that Exploration marks a major step forward for single B cell screening in antibody discovery; it brings meaningful benefits in processing speed, throughput power, hit recovery that stands out, and user-friendliness paired with dependability. The platform runs quickly — each run takes about 1.5 hours — so you can do several runs every day, and it delivers 10 times the single cell screening throughput that other instruments offer. That screening capacity comes together with the power to quickly sort thousands of live cells, which supports large-scale repertoire mining. Beyond that speed and those advanced features, the instrument was built so that everything from installation to training to everyday operation stays simple and robust. There is no fluidics whatsoever in the system, which means setup is straightforward and maintenance needs stay low. AI-assisted analysis goes through images on its own to locate hits, which brings faster speeds along with less labor and fatigue for users. Because the AI models learn from what skilled users do, someone new can tap into that know-how, which makes the product simpler to pick up and cuts down on how much instruction they need. At this point I'll hand things to Matt, who will walk through a few business-side items tied to the rollout of Exploration.
Matt Foehr
executiveAppreciate it, Bob. Looking at things commercially—and I've moved on to slide 15 now—we anticipate that Exploration is going to broaden the variety of revenue streams we draw from technology. This instrument, manufactured right here in the United States, can be obtained by our partners at a list price of roughly $500,000. On top of that, partners must subscribe to a service that handles proprietary software along with maintenance, and beyond that, there are proprietary consumables required whenever the instrument is operated for a run. This new thing we're providing to partners has us genuinely thrilled, and even as I mention all of that, I want to stress that licensing novel discovery technology to the pharmaceutical industry—our core business—is and continues to be the bedrock of our strategy, and that's what has generated steady growth in key partner and program metrics across multiple years. None of that has shifted; we regard offering Exploration to partners as additive and as an organic strategic upgrade that widens and lifts what we already provide in a manner that's highly scalable and highly leverageable; we believe the timing is right now, given that we're fast approaching 100 active OmniAb partners. Growing this business is something we're deeply dedicated to, with a sharp emphasis on value creation and profitability over the long haul. Through always putting innovation first, along with efficiency and building leverage into the business, our goal is to strengthen our position and supply sustainable value to every one of our stakeholders. We anticipate that launching Exploration will boost earnings as well as cash flow, both near term and far term. Finally, from my side, on slide 16, there's a rundown of several technical presentations coming up. Next week at the PEGS conference over in Boston, we'll clearly be featuring Exploration quite heavily, and a partner of ours that adopted early via a collaboration will also present data connected to Exploration. With that said, I'll hand the call back to Kurt so he can go over our Q1 financial results. Kurt.
Kurt Gustafson
executiveThank you, Matt. I'll pick up on slide 18, where we review first-quarter 2025 revenue. We brought in more than expected — $4.2 million, compared with $3.8 million in the same period of 2024. The primary factor was a rise in milestone revenue connected to the phase one milestone that signals the launch of GenMab's 1078 clinical program. That was partially offset by a drop in service revenue, which came after the completion of several small molecule ion channel programs. Royalty revenue also landed under what we recorded in the first quarter of 2024. Turning to slide 19, you'll see operating expenses for Q1 2025. Operating expense declined to $23 million, from $26.4 million in the year-ago period. Breaking it down: R&D expense was $12.6 million, against $14.6 million a year earlier, and that decrease stems mostly from lower stock-based compensation expense, along with reduced external expenses tied to small molecule ion channel programs and technology development. G&A expense dropped to $7.9 million from $8.3 million in the same quarter of 2024, largely because of lower legal fees and less stock-based comp. On slide 20, at the lower part of the P&L, our net loss for Q1 2025 was $18.2 million, or $0.17 per share, versus a net loss of $19 million, or $0.19 per share, in the same period of 2024. Now to slide 21, showing our balance sheet as of March 31, 2025. We ended the quarter with $43.6 million in cash, in line with our expectations. The first quarter is generally when our cash use is heaviest, and like in prior years, some seasonal compensation items fall in Q1; on top of that, as we said before, we did a reduction in force in early February, which meant roughly $1 million more in cash outlay during the first quarter. Even so, looking ahead we expect to gain from lower expenses and less cash use. On 2025 guidance, here on slide 22, you'll see we continue to expect revenue for 2025 to land between $20 million and $25 million; our 2025 revenue guidance includes no revenue contribution from the launch of the Exploration Partner Access Program. Right now, it's difficult to predict the precise number and timing of instruments we might sell to our partners. That said, as Matt noted, feedback from some of our early conversations has been quite encouraging, and we believe this program will be accretive to both earnings and cash flow. On operating expense guidance, we now expect operating expense to fall in the range of $85 million to $90 million, under our previous range of $90 million to $95 million. As a reminder, about 40% of our operating expense is non-cash, coming from depreciation, amortization, and stock-based compensation. In addition, we still expect the amount of cash we use during 2025 to come in below what we used during 2024. Just to remind everyone, the cash we used in 2024 totaled $38.9 million, excluding the ATM issuance from 2024. Regarding the tax rate, our projection is unchanged — it remains at about 0%. That said, I'd like to begin taking questions from those on the call. Operator.
Michael Cherny
analystHello. Michael here, sitting in for Puneet. I appreciate you taking my question. The first thing I want to ask about concerns how many programs got underway during this quarter. That figure is quite impressive. If I'm not mistaken, you've reached nearly 50% of the total you achieved across the entire prior year. I'd like to know whether you can tie that to specific patterns, and if the momentum was spread evenly by region or by partner size, meaning big pharma as opposed to mid-cap companies.
Matt Foehr
executiveYes, Michael, thank you. As I mentioned during my earlier comments, and as we discussed on our Q4 call if I recall correctly, we observed encouraging momentum in additions toward the close of 2024, and that carried forward into the opening quarter of 2025. Honestly, many elements are behind this. Innovation has kept going. Clearly, we've introduced new technologies alongside new workflow improvements across recent years. OmniAb, our single-chain antibody technology, has generated substantial interest among new partners, and we keep seeing current partners kick off fresh programs; that's pleasing to observe. I always temper that by noting that starts and attrition may be uneven. Things such as the timing of reports we might receive from partners, whether quarterly, biannual, or annual, come into play, correct? Certain of those elements can cause irregularity in starts and attrition, yet on the whole, it was wonderful to watch the momentum in new program additions from the close of last year carry into Q1 too. I believe that speaks volumes not just about what the team is accomplishing, but likewise about the technologies themselves and the innovation surrounding them.
Michael Cherny
analystThanks. My next question concerns the Exploration platform. I simply want to confirm my understanding is correct. This is only for partners who can use your wider platform, rather than any hypothetical pharmaceutical business. I was curious about what the added expense of promoting this offering would be, and how that fits with the reduction in the OpEx guide that you provided.
Matt Foehr
executiveYes, yes. Thanks, Michael. First off, I'll confirm that this is a partner access program; it makes OmniAb instruments and the related consumables, and so on, accessible to those within the OmniAb partner ecosystem, which numbered 95 partners at the close of Q1. That essentially addresses the first question. As you know, we revised our expense guidance today. We've been aware of and preparing for the launch of the Exploration partner access program for some time. We've arranged our organization and our plans to match. We're prepared for it; we're set up for it, and that is essentially incorporated into our financial plans too.
Michael Cherny
analystThank you very much.
Matt Foehr
executiveThanks, Michael.
Analyst
analystHello, this is Alex calling in from Frucrepa. I've got another question regarding the Exploration Partner Access Program. I realize you mentioned that figuring out how many potential partners exist is somewhat speculative right now, but if you could offer any detail, any reference points, or upper and lower bounds to frame that, it would really help. My guess is that many of these partners already own their own machinery, so they might need to determine whether an upgrade makes sense. How quickly do you think these partnership talks would move when it comes to Exploration? Do you picture sending an email to every partner and having it roll out almost immediately, or would bringing each partner on board require a certain amount of time? Thank you.
Matt Foehr
executiveYes, yes. Thank you, Alex. That's an excellent question. Clearly, the group of partners we work with has expanded steadily at double-digit rates for several years running now. Like I mentioned, we've reached 95 partners. In practical terms, only a subset of those partners represent the strongest and most probable fits for an Exploration instrument or multiple Exploration instruments, based on the type of work they perform; we already know which people those are. We're fortunate to have built strong ties with our partners. Those technical relationships run deep. In certain cases, they go back multiple years; we have a clear picture of what they're capable of. We have a clear picture of what they're interested in researching. That's what guides the way we'll approach each different partner. As I noted earlier, we've already held initial discussions with certain partners. The feedback has been extremely favorable and quite encouraging, though pinning down precise figures right now is hard to do. My expectation is that as the launch progresses further, we'll share additional details on that going forward. We'll be attending the PEGS conference in Boston next week, which ranks among the biggest gatherings for protein engineering. Several talks will focus on Exploration. We'll even have an instrument set up at our booth, and we'll share more at that point; for now it's a matter of staying tuned, but once again, we're thrilled to make this available to our partners. We believe it will make their workflows more efficient. It opens up additional revenue streams for us, not just from the instruments, but also from consumables, software maintenance, and so on.
Analyst
analystThank you. It's wonderful to witness every bit of the advancement and the fresh development. Appreciate it.
Joe Pantginis
analystHi there, everyone. Good afternoon. We appreciate you fielding our questions. Congratulations on the public launch of Exploration, and I was hoping to get a bit more detail. Clearly, you zeroed in on one crucial aspect of the differentiation, which was throughput and time. Are there additional important differentiators worth mentioning?
Matt Foehr
executiveYes, several. In a straightforward way, Joe, and I'll let Bob weigh in and add to this. It's genuinely a very simple device to operate, and it's extremely efficient. Naturally, it works very well alongside big data management, something we've discussed extensively as we've introduced new offerings such as our OmniDeep and our OmniHub platforms. In fact, I'll hand things to Bob so he can perhaps walk us through that.
Bob Chen
executiveYeah, I believe the headline figures — throughput, screening, and speed — those are quite evident. Another point worth mentioning is that we've genuinely brought this technology to maturity through live discovery campaigns we've run ourselves. That maturity likely stems from how the technology was built around a system with no fluidics, correct? Frequently, with these kinds of instruments, fluidics proves to be a major vulnerability; it leads to leaks and clogs. It can create certain problems in that area, yet our system is extremely straightforward; that additionally renders it quite simple to operate day to day, right? We truly polished the software, so that leveraging these AI tools assists you in even navigating it, with a guided scan and all of that, meaning this instrument is accessible even to junior people in the lab.
Joe Pantginis
analystThat actually helps a lot. Thank you. I'd imagine that for a person working right there in the lab, simply having that lower clogging pitch could make a big difference. As a follow-up to the earlier question, I wanted to find out whether you have any perspective at all on the revenue opportunity, first of all. And given Exploration, plus the fact that yours is a company with a heavy technology focus — initially it's good to learn that the asset is manufactured in the US, but once you consider the individual components and everything else that's required, including all the supplies, for your existing platforms, I almost feel uncomfortable posing this, but what effect are tariffs having at the moment, and how are you thinking about that now or possibly over the intermediate term when it comes to your cost?
Matt Foehr
executiveYes, Joe, I can address tariffs. Kurt is able to walk through a few of the other points. For Exploration as well as throughout our business, we genuinely don't anticipate meaningful tariff effects, and there are many reasons for that. The Exploration instrument, along with the great majority of its parts, is entirely in the U.S. The instrument gets assembled in the U.S. That's how we've structured our supply chain. Kurt, perhaps you'd like to address the other question.
Kurt Gustafson
executiveRight, and when it comes to the other items we rely on in our operations — additional lab supplies, that sort of thing — those are pretty simple, and there are several vendors available to us; honestly, we just don't see, plus it's a minor portion of our total operating expense. From any of these tariffs, we anticipate almost no effect, if there is one at all.
Joe Pantginis
analystGreat to hear. Thanks, guys.
Kurt Gustafson
executiveThanks, Joe.
Analyst
analystHey everyone, Tuliane here, filling in for Stefell. Nice work on the progress. My question is about the Exploration platform. To start, I get that it's offered to current partners via this partner access program. I'm curious whether any trend exists. Matt, I know you just said there have been continuing talks with possible partners. Do you notice a pattern in what targets partners go after, or in the signals, or even in partner size — big versus small, mid-cap firms, and so on? And second, purely out of curiosity, could this program someday be opened up to, say, brand-new partners rather than only present ones? That's what I wanted to ask. Thanks.
Matt Foehr
executiveYeah, those are great questions. I'll start with the second one, or the last one. When new partners come on board, they'll get access to the Exploration platform too, correct? For example, whenever we bring on new partners, we're constantly working out new deals. Those partners will likewise receive access and the option to buy an Exploration instrument from us, plus the option to buy the custom and proprietary consumables; that will keep going as we bring on additional partners; as for what you asked about particular targets and that sort of thing, that becomes one of the wonderful aspects of our place in the industry, with an expanding platform of active programs now at 378, a solid stream of new programs being added, and these kinds of deep relationship partnerships — you truly gain a strong sense of not just where the industry stands, where it has been, where it is today, and where it is going. Part of that, we witness a great deal of diversity once you go deep into our portfolio. Part of it also ties to the technologies we roll out. We rolled out OmniAb a couple of years back. With that rollout, we certainly observed a rise in things such as CNS disease, infectious disease, use for ADCs and multi-specifics, right? All of those are areas where we keep seeing expanding interest within the industry. Naturally, there's always steady interest in oncology, in INI, and in numerous areas, and metabolic disease, aging, those sorts of things. We observe that through our pipeline too. I genuinely can't give specific targets that people are working on. Typically, those become apparent as partners reach the clinic and as they sort of move into downstream clinical development.
Analyst
analystThanks.
Tala Phan
analystHi there, Tala Phan here, calling in from Matt Hewitt. Given the recent FDA ruling to step back from animal testing, how does that affect your business outlook, particularly as you roll out the Exploration platform? I'd love some specifics on that. Thanks.
Matt Foehr
executiveYeah. What I believe you're alluding to is an FDA statement that came out about basically reworking certain requirements, from a toxicology screening standpoint, for antibody-based medicines prior to their entering the clinic. Let me be clear: that has nothing to do with what our company offers, which is transgenic animals yielding wide-ranging bespoke antibody repertoires triggered by antigens that our partners can subsequently screen, correct? That's an entirely separate segment of the industry. It was genuinely encouraging to hear the FDA say they were examining ways to smooth the path into the clinic, which throughout the industry might help antibody-based medicines reach the clinic sooner; that's how we tend to view it. What I mean is, there could be upside if it shortens timelines for particular partners or particular programs, or if it draws additional partners toward an antibody-based modality; it might also lower the expense of bringing antibody-based medicines into the clinic, and we regard that as an upside too. There's a scientific rationale behind why this pertains to antibody-based medicines, since when you conduct in vitro work with them, you're able to gain a far clearer picture of where they're headed and what they're doing. That's among the reasons I believe the FDA issued that statement at a foundational level. On the whole, we view it as potentially welcome news for the industry. Appreciate it. Thank you.
Jackie Quinn
analystHi there, Jackie here filling in for Brendan. I appreciate you letting me ask. I suppose I'll jump on the same trend too — getting straight into the Exploration Access program seems genuinely impressive. Are you planning to create more computational or AI-based platform products or data bundles for clients as a kind of independent partner SaaS option? Is there any particular model, data set, or pocket of unmet need that you feel would be ideal for your platform to really explore?
Matt Foehr
executiveYes — prior to Bob weighing in on this, I'm certain Bob has plenty of points he could contribute here, but let me just say, Jackie, I appreciate the question. What I think comes through implicitly in what you're asking is how our different technologies introduced across recent years tie together, correct? We've been quite deliberate in our actions whenever we've rolled out offerings such as our OmniDeep platform, a collection of in silico instruments integrated across our discovery platform, encompassing Exploration and, crucially, Exploration. During the prior year, we additionally introduced our OmniHub platform, a digital offering for sharing data and tools, that sort of thing. Bob is able to discuss the constantly changing aspects of applying AI along with large-scale data management and where that fits in.
Bob Chen
executiveYeah, there are a few points to make there. I'd say Exploration's fundamental strength lies in screening millions of biological variants and then identifying thousands of positive hits, correct? To accomplish that, naturally, we rely on AI-driven tools to bolster that workflow — really to make sense of the image analysis, to assist the user in obtaining the final profile. Broadly speaking, we see Exploration as an excellent means of generating vast quantities of data, vast quantities of functional data, especially in our hands when it comes to antibodies targeting various targets. We truly consider Exploration a method for producing a substantial volume of data to supply AI tools and, in our hands, to supply OmniDeep. There's also a reciprocal dynamic at play — as we deploy AI tools to choose repertoires, to choose antibodies of interest, that sequence space can in fact return to Exploration for testing, correct? Exploration genuinely occupies a rather distinctive position to reap certain advantages as AI tools become increasingly advanced, both to make the discovery process simpler and perhaps to augment the data gathering that feeds new model training.
Jackie Quinn
analystThat's excellent. I really appreciate the detail, and I'll wait so others can participate.
Kurt Gustafson
executiveThank you, Jackie. Appreciate it, Jackie.
Matt Foehr
executiveOkay, thanks, operator. I want to express appreciation to all of you for being on today's call, as well as for your involvement and the questions you've raised. During the coming weeks, we'll be on the road attending a range of investor conferences along with scientific and technical gatherings, and we're eager to keep all of you informed. Many thanks once more.
Operator
operatorEveryone, that brings us to the end of today's call. We appreciate you joining us. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.